Literature DB >> 29504720

Durvalumab in Stage III Non-Small-Cell Lung Cancer.

Mehmet D Copur1,2, Dron Gauchan1, Ryan Ramaekers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29504720     DOI： 10.1056/NEJMc1716426

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer.

Authors:  Fei Wu; Yanzi Gu; Bin Kang; Fabienne Heskia; Alexandre Pachot; Marc Bonneville; Ping Wei; Ji Liang
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 2.  Small-Molecule Targets in Tumor Immunotherapy.

Authors:  Hui-Fang Zhu; Yan Li
Journal:  Nat Prod Bioprospect       Date:  2018-07-05

Review 3.  New developments in brain metastases.

Authors:  Anna S Berghoff; Matthias Preusser
Journal:  Ther Adv Neurol Disord       Date:  2018-06-28       Impact factor: 6.570
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.